Citation Impact
Citing Papers
Tumour-cell invasion and migration: diversity and escape mechanisms
2003 Standout
Cytochrome P450 and Non–Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics
2016
Intestinal Transport of Irinotecan in Caco-2 Cells and MDCK II Cells Overexpressing Efflux Transporters Pgp, cMOAT, and MRP1
2002
Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9
2009
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
2003
Structure and function of matrix metalloproteinases and TIMPs
2006 Standout
A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
2005
Matrix metalloproteinases and angiogenesis
2005
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells
2006
Inflammation and cancer
2002 StandoutNature
From traditional Chinese medicine to rational cancer therapy
2007 Standout
CLINICAL STUDIES OF CAMPTOTHECIN AND DERIVATIVES
2003
Tubulin interacting agents: Novel taxanes and epothilones
2003
Organocatalytic cascade reactions as a new tool in total synthesis
2010 Standout
Natural products: An evolving role in future drug discovery
2011 Standout
Marine natural products
1990 Standout
The pathogenesis of cardiac fibrosis
2013 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin
2004
Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer
2004 Standout
Strategies for MMP inhibition in cancer: innovations for the post-trial era
2002
HSP90 and the chaperoning of cancer
2005 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations
2009 Standout
Inflammation and Colon Cancer
2010 Standout
Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2
2006
Targeting multidrug resistance in cancer
2006 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Preparation of Large Monodisperse Vesicles
2009 StandoutNobel
Quantitation of camptothecin and related compounds
2001
Development and characterization of a novel liposome-based formulation of SN-38
2003
Recent advances in MMP inhibitor design
2006
Angiogenesis in life, disease and medicine
2005 StandoutNature
Nanobiohybrids as delivery vehicles for camptothecin
2004
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Matrix metalloproteinases as modulators of inflammation and innate immunity
2004 Standout
Analysis of anticancer drugs: A review
2011 Standout
Collagens—structure, function, and biosynthesis
2003 Standout
A Simple Enantioconvergent and Chemoenzymatic Synthesis of Optically Active α‐Substituted Amides
2011 StandoutNobel
Metalloproteinases and their inhibitors in tumor angiogenesis
2005
Camptothecin and its analogues: a review on their chemotherapeutic potential
2005
9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS
2002
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma
2002
The ChEMBL database in 2017
2016 Standout
Small cell lung cancer: the importance of the extracellular matrix
2004
Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration
2004
MMPs as therapeutic targets—Still a viable option?
2007
Natural compounds for cancer treatment and prevention
2009 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Novel formulations of taxanes: a review. Old wine in a new bottle?
2005
Liposomes as nanomedical devices
2015 Standout
Herb-Drug Interactions
2005 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
2007
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Cancer as an evolutionary and ecological process
2006 Standout
Natural products in drug discovery
2008 Standout
Analytical approaches for traditional Chinese medicines exhibiting antineoplastic activity
2001
Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat
2005
Angiogenesis inhibitors under study for the treatment of lung cancer
2003
Camptothecins
2002
Matrix metalloproteinases and tumor metastasis
2006 Standout
Role of matrix metalloproteinases in melanoma cell invasion
2005
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
2010 StandoutNobel
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
2002
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
2002
Separation methods for camptothecin and related compounds
2001
Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
2003
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
2005
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
2009
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
In Vivo Imaging of Matrix Metalloproteinase 12 and Matrix Metalloproteinase 13 Activities in the Mouse Model of Collagen‐Induced Arthritis
2013 StandoutNobel
VEGF Secreted by Hypoxic Müller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy
2013 StandoutNobel
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
2001
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary Malignancies
2004
Natural and Designed Proteins Inspired by Extremotolerant Organisms Can Form Condensates and Attenuate Apoptosis in Human Cells
2022 StandoutNobel
Pharmacological Effects of Formulation Vehicles
2003
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Of Mice and Not Men: Differences between Mouse and Human Immunology
2004 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
2003
Roles of NF-κB in Cancer and Inflammatory Diseases and Their Therapeutic Approaches
2016 Standout
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
2017
Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003.
2003
The Traditional Medicine and Modern Medicine from Natural Products
2016 Standout
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis
2009
Berberine Suppresses TNF-α-induced MMP-9 and Cell Invasion through Inhibition of AP-1 Activity in MDA-MB-231 Human Breast Cancer Cells
2008
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
2006
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
2003
Works of Elora Gupta being referenced
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer
1999
High-performance liquid chromatographic quantitation of total and lactone 20(S)camptothecin in patients receiving oral 20(S)camptothecin
1998
Pharmacokinetics of Orally Administered Camptothecins
2000
A Phase I Study of Oral BMS-275291, a Novel Nonhydroxamate Sheddase-Sparing Matrix Metalloproteinase Inhibitor, in Patients with Advanced or Metastatic Cancer
2004
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
2002
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291.
2001
In vitro activation of irinotecan to SN-38 by human liver and intestine.
1999
Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel
2001